Phase II study of afatinib for non-small cell lung cancer acquired resistance to osimertinib (North Japan Lung Cancer Study Group 1801)
Phase 2
Recruiting
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000030399
- Lead Sponsor
- Iwate medical university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. ILD or pulmonary fibrosis complication on chest X-ray 2. Other cancers 3. With severe complication 1). Uncontrollable pericardial effusion, pleural effusion, or ascites 2). Uncontrollable diabetes 3). Uncontrollable hypertension, angina pectoris, or heart failure 4). SVC syndrome or spinal cord pressure symptom 5). Severe infectious disease 4. Impossible to take drugs orally 5. History of serious drug allergies 6. Pregnancy, breast feeding, or hesitation in contraception 7. Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method